Treatment Outcomes of Patients With Hunner Interstitial Cystitis Who Received Augmentation Enterocystoplasty or Bladder-Preserving Therapy
Purpose: To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC).Methods: From 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving...
Uložené v:
| Vydané v: | International neurourology journal Ročník 29; číslo 3; s. 172 - 180 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Korea (South)
Korean Continence Society
01.09.2025
대한배뇨장애요실금학회 |
| Predmet: | |
| ISSN: | 2093-6931, 2093-4777, 2093-6931 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Purpose: To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC).Methods: From 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving therapy were retrospectively analyzed. Treatment outcomes were analyzed using the subjective global assessment response, symptoms, and urodynamic parameters. The patients’ symptoms and urodynamic parameters were compared between AE and non-AE groups from baseline to follow-up endpoint.Results: A total of 54 patients (48 women and 6 men) were included with a mean age of 58.6±11.4 years at diagnosis and a mean follow-up period of 9.4±5.8 years. AE and non-AE therapy was performed in 17 (31.5%) and 37 patients (68.5%), respectively. A final satisfactory outcome was reported in 13 (76.5%) of the 17 HIC patients after AE and in 26 of the 37 patients (70.3%) after non-AE therapy. Compared with patients who had no improvement, patients who had improved outcomes after AE exhibited decreased interstitial cystitis symptom index (P=0.007) and visual analogue scale (P=0.013) scores and increased bladder fullness sensation (P=0.002) and cystometric bladder capacity (P=0.019). Patients who had no improved outcomes after AE did not experience pain relief or increased bladder fullness sensation or bladder capacity. Only 23.4% of the patients treated with AE required repeat surgery or intravesical therapy in the first 1–3 years. By contrast, patients treated with non-AE therapy required repeat intravesical therapy for the recurrence of Hunner lesions or bladder symptoms.Conclusions: Both AE or non-AE therapy can result in satisfactory outcomes in more than 70% of HIC patients. AE provides early relief of bladder pain and increases bladder capacity, and non-AE therapy can also relieve pain and improve functional bladder capacity, resulting in improved outcomes. |
|---|---|
| AbstractList | Purpose To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC). Methods From 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving therapy were retrospectively analyzed. Treatment outcomes were analyzed using the subjective global assessment response, symptoms, and urodynamic parameters. The patients’ symptoms and urodynamic parameters were compared between AE and non-AE groups from baseline to follow-up endpoint. Results A total of 54 patients (48 women and 6 men) were included with a mean age of 58.6±11.4 years at diagnosis and a mean follow-up period of 9.4±5.8 years. AE and non-AE therapy was performed in 17 (31.5%) and 37 patients (68.5%), respectively. A final satisfactory outcome was reported in 13 (76.5%) of the 17 HIC patients after AE and in 26 of the 37 patients (70.3%) after non-AE therapy. Compared with patients who had no improvement, patients who had improved outcomes after AE exhibited decreased interstitial cystitis symptom index (P=0.007) and visual analogue scale (P=0.013) scores and increased bladder fullness sensation (P=0.002) and cystometric bladder capacity (P=0.019). Patients who had no improved outcomes after AE did not experience pain relief or increased bladder fullness sensation or bladder capacity. Only 23.4% of the patients treated with AE required repeat surgery or intravesical therapy in the first 1–3 years. By contrast, patients treated with non-AE therapy required repeat intravesical therapy for the recurrence of Hunner lesions or bladder symptoms. Conclusions Both AE or non-AE therapy can result in satisfactory outcomes in more than 70% of HIC patients. AE provides early relief of bladder pain and increases bladder capacity, and non-AE therapy can also relieve pain and improve functional bladder capacity, resulting in improved outcomes. Purpose: To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC). Methods: From 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving therapy were retrospectively analyzed. Treatment outcomes were analyzed using the subjective global assessment response, symptoms, and urodynamic parameters. The patients’ symptoms and urodynamic parameters were compared between AE and non-AE groups from baseline to follow-up endpoint. Results: A total of 54 patients (48 women and 6 men) were included with a mean age of 58.6±11.4 years at diagnosis and a mean follow-up period of 9.4±5.8 years. AE and non-AE therapy was performed in 17 (31.5%) and 37 patients (68.5%), respectively. A final satisfactory outcome was reported in 13 (76.5%) of the 17 HIC patients after AE and in 26 of the 37 patients (70.3%) after non-AE therapy. Compared with patients who had no improvement, patients who had improved outcomes after AE exhibited decreased interstitial cystitis symptom index (P=0.007) and visual analogue scale (P=0.013) scores and increased bladder fullness sensation (P=0.002) and cystometric bladder capacity (P=0.019). Patients who had no improved outcomes after AE did not experience pain relief or increased bladder fullness sensation or bladder capacity. Only 23.4% of the patients treated with AE required repeat surgery or intravesical therapy in the first 1–3 years. By contrast, patients treated with non-AE therapy required repeat intravesical therapy for the recurrence of Hunner lesions or bladder symptoms. Conclusions: Both AE or non-AE therapy can result in satisfactory outcomes in more than 70% of HIC patients. AE provides early relief of bladder pain and increases bladder capacity, and non-AE therapy can also relieve pain and improve functional bladder capacity, resulting in improved outcomes. KCI Citation Count: 0 To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC).PURPOSETo investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC).From 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving therapy were retrospectively analyzed. Treatment outcomes were analyzed using the subjective global assessment response, symptoms, and urodynamic parameters. The patients' symptoms and urodynamic parameters were compared between AE and non-AE groups from baseline to follow-up endpoint.METHODSFrom 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving therapy were retrospectively analyzed. Treatment outcomes were analyzed using the subjective global assessment response, symptoms, and urodynamic parameters. The patients' symptoms and urodynamic parameters were compared between AE and non-AE groups from baseline to follow-up endpoint.A total of 54 patients (48 women and 6 men) were included with a mean age of 58.6±11.4 years at diagnosis and a mean follow-up period of 9.4±5.8 years. AE and non-AE therapy was performed in 17 (31.5%) and 37 patients (68.5%), respectively. A final satisfactory outcome was reported in 13 (76.5%) of the 17 HIC patients after AE and in 26 of the 37 patients (70.3%) after non-AE therapy. Compared with patients who had no improvement, patients who had improved outcomes after AE exhibited decreased interstitial cystitis symptom index (P=0.007) and visual analogue scale (P=0.013) scores and increased bladder fullness sensation (P=0.002) and cystometric bladder capacity (P=0.019). Patients who had no improved outcomes after AE did not experience pain relief or increased bladder fullness sensation or bladder capacity. Only 23.4% of the patients treated with AE required repeat surgery or intravesical therapy in the first 1-3 years. By contrast, patients treated with non-AE therapy required repeat intravesical therapy for the recurrence of Hunner lesions or bladder symptoms.RESULTSA total of 54 patients (48 women and 6 men) were included with a mean age of 58.6±11.4 years at diagnosis and a mean follow-up period of 9.4±5.8 years. AE and non-AE therapy was performed in 17 (31.5%) and 37 patients (68.5%), respectively. A final satisfactory outcome was reported in 13 (76.5%) of the 17 HIC patients after AE and in 26 of the 37 patients (70.3%) after non-AE therapy. Compared with patients who had no improvement, patients who had improved outcomes after AE exhibited decreased interstitial cystitis symptom index (P=0.007) and visual analogue scale (P=0.013) scores and increased bladder fullness sensation (P=0.002) and cystometric bladder capacity (P=0.019). Patients who had no improved outcomes after AE did not experience pain relief or increased bladder fullness sensation or bladder capacity. Only 23.4% of the patients treated with AE required repeat surgery or intravesical therapy in the first 1-3 years. By contrast, patients treated with non-AE therapy required repeat intravesical therapy for the recurrence of Hunner lesions or bladder symptoms.Both AE or non-AE therapy can result in satisfactory outcomes in more than 70% of HIC patients. AE provides early relief of bladder pain and increases bladder capacity, and non-AE therapy can also relieve pain and improve functional bladder capacity, resulting in improved outcomes.CONCLUSIONBoth AE or non-AE therapy can result in satisfactory outcomes in more than 70% of HIC patients. AE provides early relief of bladder pain and increases bladder capacity, and non-AE therapy can also relieve pain and improve functional bladder capacity, resulting in improved outcomes. To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial cystitis (HIC). From 2013 to 2024, patients with cystoscopically confirmed HIC who received AE or non-AE bladder-preserving therapy were retrospectively analyzed. Treatment outcomes were analyzed using the subjective global assessment response, symptoms, and urodynamic parameters. The patients' symptoms and urodynamic parameters were compared between AE and non-AE groups from baseline to follow-up endpoint. A total of 54 patients (48 women and 6 men) were included with a mean age of 58.6±11.4 years at diagnosis and a mean follow-up period of 9.4±5.8 years. AE and non-AE therapy was performed in 17 (31.5%) and 37 patients (68.5%), respectively. A final satisfactory outcome was reported in 13 (76.5%) of the 17 HIC patients after AE and in 26 of the 37 patients (70.3%) after non-AE therapy. Compared with patients who had no improvement, patients who had improved outcomes after AE exhibited decreased interstitial cystitis symptom index (P=0.007) and visual analogue scale (P=0.013) scores and increased bladder fullness sensation (P=0.002) and cystometric bladder capacity (P=0.019). Patients who had no improved outcomes after AE did not experience pain relief or increased bladder fullness sensation or bladder capacity. Only 23.4% of the patients treated with AE required repeat surgery or intravesical therapy in the first 1-3 years. By contrast, patients treated with non-AE therapy required repeat intravesical therapy for the recurrence of Hunner lesions or bladder symptoms. Both AE or non-AE therapy can result in satisfactory outcomes in more than 70% of HIC patients. AE provides early relief of bladder pain and increases bladder capacity, and non-AE therapy can also relieve pain and improve functional bladder capacity, resulting in improved outcomes. |
| Author | Lee, Yu-Shuang Jiang, Yuan-Hong Chen, Sheng-Fu Chang, Tien-Lin Jhang, Jia-Fong Kuo, Hann-Chorng |
| Author_xml | – sequence: 1 givenname: Yu-Shuang surname: Lee fullname: Lee, Yu-Shuang – sequence: 2 givenname: Tien-Lin orcidid: 0009-0001-0317-3420 surname: Chang fullname: Chang, Tien-Lin – sequence: 3 givenname: Sheng-Fu orcidid: 0000-0003-1761-1185 surname: Chen fullname: Chen, Sheng-Fu – sequence: 4 givenname: Jia-Fong orcidid: 0000-0001-6674-2152 surname: Jhang fullname: Jhang, Jia-Fong – sequence: 5 givenname: Yuan-Hong orcidid: 0000-0002-7870-1574 surname: Jiang fullname: Jiang, Yuan-Hong – sequence: 6 givenname: Hann-Chorng orcidid: 0000-0001-7165-4771 surname: Kuo fullname: Kuo, Hann-Chorng |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/41077790$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003251619$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNpNkk1rGzEQhkVJadI0596KjiWwjlYfq92ja9LEEEgILj0KrXbWlrOWXEkb8F_or4780VBdZhieeWcYvZ_RmfMOEPpakomgJbuxbj2hQhDCqgkp6w_ogpKGFVXDyrP_8nN0FeOa5Me5JEJ-Que8JFLKhlygv4sAOm3AJfw4JuM3ELHv8ZNONtci_m3TCt-PzkHAc5cgxGST1QOe7Q5ZJlYeP4MB-wodno7LvVbu9g7f7nlvMui3g45ph33APwbddRCKpwARwqt1S7xYQdDb3Rf0sddDhKtTvES_ft4uZvfFw-PdfDZ9KAxrRCq6jjPZyM7wUoiS0LbJB5AaSkYMh6aqRaUZhdpAzTlvmZAgKZWkFaYiBji7RNdHXRd69WKs8toe4tKrl6Cmz4u5yvepeCn38PwId16v1TbYjQ67Q8eh4MNS6ZCsGUD1LeU1raWpteCa8abKa7ZEkLapdF40a30_am2D_zNCTGpjo4Fh0A78GBWjFeGE5o6MfjuhY7uB7n3wv4_LwM0RMMHHGKB_R0qi9u5Q2R3q5A6V3cHeADH2rCs |
| Cites_doi | 10.4103/tcmj.tcmj_172_23 10.1002/nau.23339 10.3109/21681805.2013.840334 10.3390/diagnostics12010075 10.1097/ju.0000000000001031 10.4103/tcmj.tcmj_313_21 10.1007/s00345-023-04581-y 10.1016/j.urology.2019.07.036 10.1007/s00345-025-05451-5 10.5213/inj.2142408.204 10.1007/s00192-020-04517-9 10.1097/ju.0000000000001811 10.1016/j.urology.2013.06.043 10.1097/us9.0000000000000016 10.1016/j.urols.2016.05.130 10.1007/s11136-022-03183-2 10.1002/nau.24997 10.1111/luts.12441 10.1007/s00345-022-04062-8 10.1097/ju.0000000000002756 10.1016/j.euros.2023.07.006 10.1186/s12894-020-00597-3 10.1080/21681805.2020.1730948 10.1002/nau.25195 10.3390/biomedicines10102380 10.1097/js9.0000000000001961 10.1111/luts.12505 10.1111/iju.14229 10.1111/bju.14097 10.3390/biomedicines12030522 10.1002/nau.23998 10.1016/j.eururo.2020.01.002 10.1001/jamanetworkopen.2024.4880 10.1016/j.euf.2020.02.014 10.3390/biomedicines9101306 10.1111/luts.12532 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION NPM 7X8 DOA ACYCR |
| DOI | 10.5213/inj.2550036.018 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2093-6931 |
| EndPage | 180 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10764174 oai_doaj_org_article_fb248287c8a54a3496797b050b96a102 41077790 10_5213_inj_2550036_018 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Buddhist Tzu Chi Medical Foundation grantid: TCMF-MP-110-03-01 – fundername: Buddhist Tzu Chi Medical Foundation grantid: TCMF-SP-112-01 |
| GroupedDBID | --- 5-W 53G 8JR 8XY AAKDD AAYXX ABDBF ACUHS ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK E3Z EBD EF. F5P GROUPED_DOAJ HYE OK1 RPM 9ZL NPM 7X8 ACYCR |
| ID | FETCH-LOGICAL-c395t-dd43797dc4155102b90037ae130c4e96856a32e8ce8444b357e72270b5c60ce43 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001586881500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2093-6931 2093-4777 |
| IngestDate | Sat Oct 04 03:10:29 EDT 2025 Mon Nov 17 19:34:23 EST 2025 Mon Oct 13 17:01:12 EDT 2025 Sat Oct 18 23:08:28 EDT 2025 Sat Nov 29 07:27:37 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Treatment outcome Bladder augmentation Bladder surgery Electrocauterization Interstitial cystitis |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c395t-dd43797dc4155102b90037ae130c4e96856a32e8ce8444b357e72270b5c60ce43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 https://doi.org/10.5213/inj.2550036.018 |
| ORCID | 0009-0001-0317-3420 0000-0001-7165-4771 0000-0003-1761-1185 0000-0002-7870-1574 0000-0001-6674-2152 |
| OpenAccessLink | https://doaj.org/article/fb248287c8a54a3496797b050b96a102 |
| PMID | 41077790 |
| PQID | 3260402050 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10764174 doaj_primary_oai_doaj_org_article_fb248287c8a54a3496797b050b96a102 proquest_miscellaneous_3260402050 pubmed_primary_41077790 crossref_primary_10_5213_inj_2550036_018 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-09-01 |
| PublicationDateYYYYMMDD | 2025-09-01 |
| PublicationDate_xml | – month: 09 year: 2025 text: 2025-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | International neurourology journal |
| PublicationTitleAlternate | Int Neurourol J |
| PublicationYear | 2025 |
| Publisher | Korean Continence Society 대한배뇨장애요실금학회 |
| Publisher_xml | – name: Korean Continence Society – name: 대한배뇨장애요실금학회 |
| References | ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 Kim (ref16) 2014 ref30 ref11 ref10 ref32 ref2 ref1 ref17 ref38 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 Jhang (ref33) 2023 |
| References_xml | – ident: ref37 doi: 10.4103/tcmj.tcmj_172_23 – start-page: 69 volume-title: Efficacy and safety of augmentation ileocystoplasty combined with supratrigonal cystectomy for the treatment of refractory bladder pain syndrome/interstitial cystitis with Hunner’s lesion> year: 2014 ident: ref16 – ident: ref23 doi: 10.1002/nau.23339 – ident: ref17 doi: 10.3109/21681805.2013.840334 – ident: ref36 doi: 10.3390/diagnostics12010075 – ident: ref3 doi: 10.1097/ju.0000000000001031 – ident: ref11 doi: 10.4103/tcmj.tcmj_313_21 – ident: ref26 doi: 10.1007/s00345-023-04581-y – ident: ref14 doi: 10.1016/j.urology.2019.07.036 – ident: ref27 doi: 10.1007/s00345-025-05451-5 – ident: ref15 doi: 10.5213/inj.2142408.204 – ident: ref7 doi: 10.1007/s00192-020-04517-9 – ident: ref20 doi: 10.1097/ju.0000000000001811 – ident: ref22 doi: 10.1016/j.urology.2013.06.043 – ident: ref30 doi: 10.1097/us9.0000000000000016 – ident: ref25 doi: 10.1016/j.urols.2016.05.130 – ident: ref38 doi: 10.1007/s11136-022-03183-2 – ident: ref8 doi: 10.1002/nau.24997 – ident: ref6 doi: 10.1111/luts.12441 – ident: ref12 doi: 10.1007/s00345-022-04062-8 – ident: ref1 doi: 10.1097/ju.0000000000002756 – ident: ref9 doi: 10.1016/j.euros.2023.07.006 – ident: ref10 doi: 10.1186/s12894-020-00597-3 – ident: ref5 doi: 10.1080/21681805.2020.1730948 – ident: ref28 doi: 10.1002/nau.25195 – ident: ref29 doi: 10.3390/biomedicines10102380 – ident: ref32 doi: 10.1097/js9.0000000000001961 – start-page: 276 volume-title: EBV infection mediated BDNF expression is associated with bladder inflammation in interstitial cystitis/bladder pain syndrome with Hunner’s lesion year: 2023 ident: ref33 – ident: ref18 doi: 10.1111/luts.12505 – ident: ref4 doi: 10.1111/iju.14229 – ident: ref13 doi: 10.1111/bju.14097 – ident: ref35 doi: 10.3390/biomedicines12030522 – ident: ref19 doi: 10.1002/nau.23998 – ident: ref31 doi: 10.1016/j.eururo.2020.01.002 – ident: ref34 doi: 10.1001/jamanetworkopen.2024.4880 – ident: ref21 doi: 10.1016/j.euf.2020.02.014 – ident: ref24 doi: 10.3390/biomedicines9101306 – ident: ref2 doi: 10.1111/luts.12532 |
| SSID | ssj0000447057 |
| Score | 2.3356478 |
| Snippet | Purpose: To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner... To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner interstitial... Purpose To investigate the long-term therapeutic satisfaction after augmentation enterocystoplasty (AE) or non-AE bladder therapy in patients with Hunner... |
| SourceID | nrf doaj proquest pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database |
| StartPage | 172 |
| SubjectTerms | bladder augmentation bladder surgery electrocauterization interstitial cystitis treatment outcome 비뇨기과학 |
| Title | Treatment Outcomes of Patients With Hunner Interstitial Cystitis Who Received Augmentation Enterocystoplasty or Bladder-Preserving Therapy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/41077790 https://www.proquest.com/docview/3260402050 https://doaj.org/article/fb248287c8a54a3496797b050b96a102 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003251619 |
| Volume | 29 |
| WOSCitedRecordID | wos001586881500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | International Neurourology Journal, 2025, 29(3), , pp.172-180 |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2093-6931 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000447057 issn: 2093-6931 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4k0KVEZw4OLWTfzKsa2oigSlh0XszYodZ7stJFU2Qdq_wK9mxs5We0FcOCWK8rD8TWa-cSbfEPJeYfMbyQNzpqiZCM4wV1SCITc2UtWh9hHpz_r83Mzn5cVWqy-sCUvywGniDhqXCxRl96aSokJ5c11qxyV3paoOk4wk1-VWMhV9sBCaR5nPHFJ2JrTWSdcHolVxsGyv9oFKoxbLPsd2H1shKSr3Q6Bp--bvpDMGn9NH5OHEGulRGu1jcie0T8j9L9N38afk92xTL06_jgMYUVjRrqEXSTR1Rb8vh0t6NmKbLRrXALFCACyPnqzjHpxx2VGgkAGcX02PxsXP6Z-klsaygc6vUYIAqPawpl1Pj3-gx-oZVnCgt2kXdJb0CZ6Rb6cfZydnbOqywHxRyoHVNUoS6tojtYAJdbi2qasAwc2LUCpArCryYHwwQghXSB10nmvupFfcB1E8Jztt14aXhArITYACyEOjGhGMqgKHG4GHaMrSl8pn5MNmou1NEtOwkIQgJhYwsRMmFjDJyDECcXsaqmDHA2AbdrIN-y_byMg7gNFe-2W8HreLzl73FnKFT_BkrQQkZBl5u4HZwruFH0yqNnTjygK15ZhfS56RFwn_2wEJuBy1Gnf_x0BfkQc59hWOtWuvyc7Qj-ENued_gQH0e-Sunpu9aOB_AEwa-gk |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+Outcomes+of+Patients+With+Hunner+Interstitial+Cystitis+Who+Received+Augmentation+Enterocystoplasty+or+Bladder-Preserving+Therapy&rft.jtitle=International+neurourology+journal&rft.au=Yu-Shuang+Lee&rft.au=Tien-Lin+Chang&rft.au=Sheng-Fu+Chen&rft.au=Jia-Fong+Jhang&rft.date=2025-09-01&rft.pub=Korean+Continence+Society&rft.issn=2093-4777&rft.eissn=2093-6931&rft.volume=29&rft.issue=3&rft.spage=172&rft.epage=180&rft_id=info:doi/10.5213%2Finj.2550036.018&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_fb248287c8a54a3496797b050b96a102 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2093-6931&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2093-6931&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2093-6931&client=summon |